Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel
NASDAQ:SYBX

Synlogic Q2 2024 Earnings Report

Synlogic logo
$0.70 0.00 (0.00%)
As of 06/2/2026 12:36 PM Eastern
ProfileEarnings HistoryForecast

Synlogic EPS Results

Actual EPS
$0.16
Consensus EPS
-$0.51
Beat/Miss
Beat by +$0.67
One Year Ago EPS
N/A

Synlogic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Synlogic Announcement Details

Quarter
Q2 2024
Date
8/8/2024
Time
N/A
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
7:15AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Synlogic's Q2 2024 Press ReleasePress Release
(8-K)
Synlogic's Q2 2024 Quarterly reportQuarterly report
(10-Q)

Synlogic Earnings Headlines

Synlogic (NASDAQ:SYBX) Stock Crosses Below 50 Day Moving Average - Time to Sell?
May 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30807337
Synlogic Challenges Nasdaq Delisting Notice
November 26, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/synlogic-challenges-nasdaq-delisting-notice?utm_source=marketbeat.com&utm_medium=referral
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it coming — but those who did walked away wealthy.Trump holds that same legal authority today. Advisors close to the administration believe he may use it.If he does, the transfer moves fast. The window to position yourself on the right side is already closing.tc pixel
June 3 at 1:00 AM  |  American Alternative (Ad)
We Think Synlogic (NASDAQ:SYBX) Can Afford To Drive Business Growth
September 18, 2025  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/think-synlogic-nasdaq-sybx-afford-105816457.html
Synlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo Finance
June 28, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/SYBX/news/
Synlogic's executive sells shares worth $2,802
February 5, 2025  |  msn.comhttps://www.msn.com/en-us/money/executive-leadership-and-management/synlogic-s-executive-sells-shares-worth-2-802/ar-AA1yq62c
See More Synlogic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synlogic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synlogic and other key companies, straight to your email.

About Synlogic

Synlogic (NASDAQ:SYBX), a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

View Synlogic Profile
Earnings Tools